法国全国理赔数据库中类似PEGASUS-TIMI 54试验患者的心梗后结局
本研究旨在描述法国全国理赔数据库中稳定的心肌梗死后患者(类似PEGASUS-TIMI 54试验人群)的真实世界结局。研究识别了心梗后1年无事件患者,随访至3年,发现PEGASUS样人群年龄更大、合并症更多,导致全因死亡和出血率更高,但心梗复发率相似。
要点
- PEGASUS样人群全因死亡和出血率高于试验安慰剂组,但心梗复发率相似。
- PEGASUS样人群较心梗后总体人群年龄更大、合并症更多。
- 事件率在3年随访期间保持稳定。
核心结论
- 使用PEGASUS标准选择的患者年龄更大、合并症更多,导致全因死亡和出血率更高,但心梗复发率相似。
研究设计与样本
- 基于法国理赔数据库代表性1/97样本(2005-2010年)的队列研究,纳入心梗后1年无事件患者并随访至3年。
主要发现
- 心梗后总体人群共1585例,总随访3926人年;PEGASUS样人群865例,随访2114人年。
- PEGASUS样人群中男性占68%,平均年龄74(标准差10)岁;心梗后总体人群平均年龄66(标准差15)岁。
- 每100人年结局[95%CI]:PEGASUS样人群 vs 心梗后总体人群,复合终点7.8[6.7-8.9] vs 6.3[5.6-7.1];死亡6.5[5.5-7.6] vs 5.1[4.4-5.8];心梗1.0[0.6-1.4] vs 1.0[0.7-1.3];卒中0.9[0.5-1.2] vs 0.6[0.4-0.9];大出血1.4[0.9-1.9] vs 1.3[0.9-1.6]。
关键数值与推荐
- PEGASUS样人群定义:年龄≥65岁,或年龄≥50岁且合并糖尿病、肾功能不全或既往心梗,且无卒中、终末期肾衰竭或口服抗凝治疗。
临床怎么用
- 临床中参照PEGASUS标准选择心梗后长期抗血小板治疗患者时,需注意真实世界人群年龄更大、合并症更多,死亡和出血风险可能高于试验。
局限性
- 研究基于法国理赔数据库,可能存在编码不准确或未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The present study aims to describe real-life outcomes in stable patients after-myocardial infarction (MI) similar to those in the PEGASUS-TIMI 54 trial (PEGASUS), which found long-term benefits of ticagrelor in patients with a history of MI. METHODS: One-year event-free post-MI patients were identified in the French claims database representative 1/97 sample (2005-2010) and followed for up to 3 years. A PEGASUS-like (PL) population included patients with age ≥ 65 years, or age ≥ 50 and diabetes, renal dysfunction or prior MI, without stroke, end-stage renal failure or oral anticoagulation. Outcomes were: a composite of all-cause death or hospital admission for MI or stroke; individual events; major bleeding. RESULTS: There were 1585 post-MI patients totalling 3926 person-years including 865 PL patients (2114 PY); 68% were male; mean age was 66 (standard deviation 15) in post-MI, 74 (10) in PL. Outcomes per 100 person-years [95% confidence interval] were, respectively, in post-MI and PL 6.3 [5.6-7.1] and 7.8 [6.7-8.9] for the composite outcome; 5.1 [4.4-5.8] and 6.5 [5.5-7.6] for death; 1.0 [0.7-1.3] and 1.0 [0.6-1.4] for MI; 0.6 [0.4-0.9] and 0.9 [0.5-1.2] for stroke; 1.3 [0.9-1.6] and 1.4 [0.9-1.9] for major bleeding. Event rates were stable over the 3 study years. Placebo patients in the PEGASUS-TIMI54 Study were younger, more often male and had lower event rates, especially for all-cause death and major bleeding. CONCLUSIONS: Patients selected using the criteria described in PEGASUS were older with more comorbidities, resulting in higher all-cause death and bleeding rates, but similar MI recurrence rates.
引用
- Blin P, Dureau-Pournin C, Lassalle R, et al. Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database. Br J Clin Pharmacol. 2017. PMID: 28345154. doi:10.1111/bcp.13291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。